With over 18 years of experience in asthma, emphysema and lung cancer markets, Broncus Holding Corporation is a commercial stage medtech company with main subsidiaries based in California, United States and Shanghai, China. The Company is dedicated to developing navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has set up a strong and comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending.

In September 2021, Broncus was listed on the Hong Kong Stock Exchange (stock code: 02216. hk).